Masaki Yoshida

List of Publications by Year
in descending order

44 papers	2,201 citations	377584 21 h-index	340414 39 g-index
44 all docs	44 docs citations	44 times ranked	1791 citing authors

#	Article	IF	Citations
1	Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition). International Journal of Urology, 2021, 28, 474-492.	0.5	18
2	Cardiovascular safety of vibegron, a new Î²3â€adrenoceptor agonist, in older patients with overactive bladder: Postâ€hoc analysis of a randomized, placeboâ€controlled, doubleâ€blind comparative phase 3 study. Neurourology and Urodynamics, 2021, 40, 1651-1660.	0.8	5
3	Efficacy of vibegron, a novel Î²3â€adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placeboâ€controlled, doubleâ€blind, comparative phase 3 study. BJU International, 2020, 125, 709-717.	1.3	15
4	Efficacy of novel Î²₃â€adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A postâ€hoc analysis of a randomized, doubleâ€blind, placeboâ€controlled phase 3 study. International Journal of Urology, 2019, 26, 369-375.	0.5	17
5	Vibegron, a Novel Potent and Selective Î²3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. European Urology, 2018, 73, 783-790.	0.9	100
6	Longâ€term safety and efficacy of the novel Î²₃â€adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase <scp>III</scp> prospective study. International Journal of Urology, 2018, 25, 668-675.	0.5	31
7	Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. International Journal of Urology, 2017, 24, 716-729.	0.5	90
8	Phase <scp>III</scp>, randomised, doubleâ€blind, placeboâ€controlled study of the Î²₃â€adrenoceptor agonist mirabegron, 50â€‰mg once daily, in <scp>J</scp>apanese patients with overactive bladder. BJU International, 2014, 113, 951-960.	1.3	122
9	Detrusor Underactivity: The Current Concept of the Pathophysiology. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 131-137.	0.6	23
10	New clinical evidence of silodosin, an Î±_{1A} selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms. International Journal of Urology, 2012, 19, 306-316.	0.5	19
11	Effects of Chronic Hyperlipidemia on Lower Urinary Tract Functionâ€"Bladder Dysfunction in Myocardial Infarctionâ€Prone Watanabe Heritable Hyperlipidemic Rabbits. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 21-26.	0.6	5
12	Efficacy of Solifenacin on Nocturia in Japanese Patients With Overactive Bladder: Impact on Sleep Evaluated by Bladder Diary. Journal of Urology, 2011, 186, 170-174.	0.2	45
13	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clinical Interventions in Aging, 2011, 6, 161.	1.3	37
14	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Pathophysiology and Pharmacotherapy of Overactive Bladder. Journal of Pharmacological Sciences, 2010, 112, 128-134.	1.1	44
15	The effects of chronic hyperlipidemia on bladder function in myocardial infarctionâ€prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourology and Urodynamics, 2010, 29, 1350-1354.	0.8	55
16	Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia. Neurourology and Urodynamics, 2010, 29, 1276-1281.	0.8	21
17	Ejaculation Disorder Is Associated With Increased Efficacy of Silodosin for Benign Prostatic Hyperplasia. Urology, 2010, 76, 1446-1450.	0.5	50
18	Neuronal Nitric Oxide Synthase Gene Transfer into the Rat Prostate Using In Vivo Electroporation. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 83-87.	0.6	0

#	Article	IF	Citations
19	Perspectives on overactive bladder in the elderly population. World Journal of Urology, 2009, 27, 729-737.	1.2	11
20	Overactive Bladder in Female Patients with Chronic Diseases Visiting Primary Care Doctors: Effect of Age on Prevalence and Bothersomeness. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 45-50.	0.6	3
21	Attenuation of Nonâ€neuronal Adenosin Triphosphate Release from Human Bladder Mucosa by Antimuscarinic Agents. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 88-92.	0.6	12
22	Pharmacological Effects of Solifenacin on Human Isolated Urinary Bladder. Pharmacology, 2008, 82, 43-52.	0.9	20
23	Basic and Clinical Aspects of Non-neuronal Acetylcholine: Expression of Non-neuronal Acetylcholine in Urothelium and Its Clinical Significance. Journal of Pharmacological Sciences, 2008, 106, 193-198.	1.1	86
24	Delivery of DNA into Bladder via Electroporation. Methods in Molecular Biology, 2008, 423, 249-257.	0.4	6
25	WS1-4-4 Anticholinergic Drugs can Suppress Non-neuronal ATP Release from Human Bladder Urothelium(Urodynamic, Prostate and Urethra). Japanese Journal of Urology, 2008, 99, 151.	0.0	0
26	Silodosin, a novel selective Î±_{1A}-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs, 2007, 16, 1955-1965.	1.9	48
27	Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score. Drugs of Today, 2007, 43 Suppl B, 1-7.	0.7	0
28	Non-neuronal cholinergic system in human bladder urothelium. Urology, 2006, 67, 425-430.	0.5	178
29	Symptom assessment tool for overactive bladder syndromeâ€"overactive bladder symptom score. Urology, 2006, 68, 318-323.	0.5	582
30	Silodosin, a new ?1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU International, 2006, 98, 1019-1024.	1.3	245
31	Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. International Journal of Urology, 2006, 13, 271-276.	0.5	43
32	CS1-3 Pharmacological Treatment(Comprehensive Study 1â€ŒTreatment Strategy for Obstinate Urinary) Tj ETQq0 0 0 rgBT /Overlock 1	0.0	0
33	Ageâ€related changes in the properties of Î± 1 â€adrenoceptors in the rat genitourinary tract. FASEB Journal, 2006, 20, A254.	0.2	0
34	Prejunctional Î±-adrenoceptors regulate nitrergic neurotransmission in the rabbit urethra. European Journal of Pharmacology, 2000, 400, 271-278.	1.7	14
35	Pharmacological effects of tolterodine on human isolated urinary bladder. European Journal of Pharmacology, 1999, 368, 223-230.	1.7	48
36	The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. European Journal of Pharmacology, 1998, 357, 213-219.	1.7	21

#	Article	IF	Citations
37	CHARACTERIZATION, LOCALIZATION AND DISTRIBUTION OF alpha 1 ADRENOCEPTOR SUBTYPE IN MALE RABBIT URETHRA. Journal of Urology, 1998, 160, 196-205.	0.2	4
38	Glycolaldehyde-Modified Low Density Lipoprotein Leads Macrophages to Foam Cells via the Macrophage Scavenger Receptor. Journal of Biochemistry, 1998, 123, 1208-1217.	0.9	43
39	Age-dependent Alterations in beta-adrenergic Responsiveness of Rat Detrusor Smooth Muscle. Journal of Urology, 1995, 153, 1701-1705.	0.2	53
40	Diabetes-Induced Alterations in the Properties of Muscarinic Cholinergic Receptors in Rat Vas Deferens. Journal of Urology, 1994, 152, 1017-1021.	0.2	15
41	Age-related changes in Ca2+ channel antagonist receptors in rabbit lower urinary tract. European Journal of Pharmacology, 1993, 232, 159-167.	1.7	8
42	The Reversal Effect of Insulin on Diabetes-Induced Alterations In Beta Adrenergic and Muscarinic Receptors in Rat Prostate. Journal of Urology, 1993, 149, 1602-1606.	0.2	29
43	Effect of Insulin and Dietary Myoinositol on Muscarinic Receptor Alterations in Diabetic Rat Bladder. Journal of Urology, 1992, 147, 760-763.	0.2	14
44	Beta adrenergic receptor alterations in diabetic rat prostate: Effects of insulin and dietary myoinositol. Prostate, 1991, 19, 121-131.	1.2	21